Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. Summary
    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/14/2021 10/15/2021 10/18/2021 10/19/2021 10/20/2021 Date
1401.8(c) 1399.6(c) 1395.6(c) 1407.2(c) 1407.8 Last
4 221 128 5 957 424 3 999 834 5 486 304 79 965 Volume
+0.06% -0.16% -0.29% +0.83% +0.04% Change
More quotes
Estimated financial data (e)
Sales 2021 33 491 M 46 172 M 46 172 M
Net income 2021 3 824 M 5 272 M 5 272 M
Net Debt 2021 21 074 M 29 053 M 29 053 M
P/E ratio 2021 18,5x
Yield 2021 5,68%
Sales 2022 35 214 M 48 548 M 48 548 M
Net income 2022 4 615 M 6 362 M 6 362 M
Net Debt 2022 19 680 M 27 132 M 27 132 M
P/E ratio 2022 15,4x
Yield 2022 3,90%
Capitalization 70 430 M 97 209 M 97 098 M
EV / Sales 2021 2,73x
EV / Sales 2022 2,56x
Nbr of Employees 94 066
Free-Float 92,3%
More Financials
Company
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business... 
Sector
Pharmaceuticals
Calendar
10/27Earnings Release
More about the company
Ratings of GlaxoSmithKline plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about GLAXOSMITHKLINE PLC
10/19'Green is good' says UK's Johnson, wooing Wall Street dollars
RE
10/19Pharnext renforce son équipe de direction avec trois nominations clés pour poursuivre l..
DJ
10/19Pharnext strengthens its management team with three key appointments to support ongoing..
DJ
10/18GLAXOSMITHKLINE : GSK to showcase significant scientific advances in renal care at the Ame..
PU
10/18Today on Wall Street: This is the real test
10/18GLAXOSMITHKLINE : Berenberg Slashes GlaxoSmithKline's PT, Keeps Rating
MT
10/18GLAXOSMITHKLINE : Berenberg Maintains GlaxoSmithKline At Buy, Trims PT
MT
10/18ANALYST RECOMMENDATIONS : Drax, GlaxoSmithKline, Goldman Sachs, JP Morgan, Steel Dynamics...
10/18GLAXOSMITHKLINE : JP Morgan reiterates its Neutral rating
MD
10/18GLAXOSMITHKLINE : Receives a Buy rating from Berenberg
MD
10/17MEDIA-Cop26 corporate sponsors condemn climate summit as ‘mismanaged’- Guardian
RE
10/15GLAXOSMITHKLINE : New Malaria Vaccine to Benefit Hundreds of Thousands of African Children
AQ
10/15GLAXOSMITHKLINE : Chairman Backs CEO After Bluebell Letter
MT
10/14GLAXOSMITHKLINE ( '') TRANSACTION NO : GlaxoSmithKline plc (the 'Company') Transaction not..
PU
10/14GLAXOSMITHKLINE : Goldman Sachs remains its Buy rating
MD
More news
News in other languages on GLAXOSMITHKLINE PLC
10/18MADRID STOCK EXCHANGE : La feria de resultados vuelve a estar en pleno apogeo
10/18STOCK MARKET PARIS : La grand-messe des résultats repart de plus belle
10/18AVIS D'ANALYSTES DU JOUR : Publicis, Eurofins, Elmos, Melexis, VAT Group, Befesa, Drax...
10/15Le président de GlaxoSmithKline soutient le PDG après la lettre Bluebell
10/14CUREVAC : la pharma abandonne son candidat-vaccin Covid et rejoint ls recherches de GSK
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | MarketScreener
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 1 407,20 GBX
Average target price 1 600,98 GBX
Spread / Average Target 13,8%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GLAXOSMITHKLINE PLC4.86%97 209
JOHNSON & JOHNSON4.12%431 385
ROCHE HOLDING AG15.84%337 562
NOVO NORDISK A/S57.04%239 813
PFIZER, INC.12.25%235 986
ELI LILLY AND COMPANY43.51%219 674